Renaissance Technologies - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 195 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2015. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$15,310
+57.4%
825,800
-6.1%
0.03%
+85.7%
Q2 2023$9,726
-31.0%
879,400
-16.3%
0.01%
-26.3%
Q1 2023$14,104
+61.0%
1,050,200
+48.3%
0.02%
+58.3%
Q4 2022$8,762
-99.9%
708,300
-4.2%
0.01%
-20.0%
Q3 2022$10,312,000
+89.8%
739,200
+87.9%
0.02%
+150.0%
Q2 2022$5,433,000
+55.2%
393,400
+82.8%
0.01%
+50.0%
Q1 2022$3,501,000
-11.8%
215,200
-11.6%
0.00%
-20.0%
Q4 2021$3,968,000
+33.9%
243,569
+22.0%
0.01%
+25.0%
Q3 2021$2,964,000
+260.6%
199,600
+460.7%
0.00%
+300.0%
Q1 2021$822,000
-92.4%
35,600
-91.9%
0.00%
-91.7%
Q4 2020$10,794,000
+6.4%
437,000
+78.6%
0.01%
+20.0%
Q3 2020$10,145,000
-33.9%
244,700
-23.6%
0.01%
-23.1%
Q2 2020$15,341,000
-20.5%
320,200
+4.5%
0.01%
-31.6%
Q1 2020$19,291,000
+68.8%
306,400
+232.3%
0.02%
+111.1%
Q4 2019$11,425,000
+1751.7%
92,200
+1707.8%
0.01%
+800.0%
Q2 2017$617,000
-94.0%
5,100
-91.7%
0.00%
-95.8%
Q3 2015$10,217,000
-31.1%
61,600
+0.3%
0.02%
-29.4%
Q2 2015$14,821,000
+591.3%
61,400
+844.6%
0.03%
+580.0%
Q1 2014$2,144,0006,5000.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2015
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders